
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Once-daily quinolone gains new urology indications: West Haven, CT-Bayer Pharmaceuticals has received FDA approval to market its once-daily, extended-release fluoroquinolone, ciprofloxacin (Cipro XR), for two new indications: complicated urinary tract infections and acute uncomplicated pyelonephritis.





